Does long-term aspirin use have any effect on helicobacter pylori eradication?

American Journal of the Medical Sciences

Volumn 342, Issue 1, 2011, Pages 15-19

  Gokturk, Huseyin Savas ^a   Demir, Mehmet ^a   Unler, Gulhan Kanat ^a   Erbayrak, Mustafa ^b   Sakalli, Murat ^b   Yilmaz, Ugur ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Konya Research and Training Hospital ^*  (Turkey)

Author keywords

Aspirin; Eradication therapy; Helicobacter pylori

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; UREA C 13;

ABDOMINAL PAIN; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PILOT STUDY; STOMACH BIOPSY; UREA BREATH TEST; VOMITING;

EID: 79959886508     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182174cf1     Document Type: Article

References (23)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 2007;56:772-81. (Pubitemid 46854190)
3. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
4. Kadayifci A. What is the best first choice treatment for Helicobacter pylori? Turk J Gastroenterol 2007;181-4.
5. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62. (Pubitemid 351664506)
6. Wang WH, Wong WM, Dailidiene D, et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 2003;52:490-5. (Pubitemid 36363398)
7. Gu Q, Xia HH, Wang WH, et al. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Aliment Pharmacol Ther 2004;20:675-81. (Pubitemid 39279056)
8. Shirin H, Moss SF, Kancherla S, et al. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori. J Gastroenterol Hepatol 2006;21:1388-93. (Pubitemid 44154705)
9. Zhang XP, Wang WH, Tian Y, et al. Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentrations of antimicrobials. World J Gastroenterol 2009;15:919-26.
10. Park SH, Park DI, Kim SH, et al. Effect of high-dose aspirin on Helicobacter pylori eradication. Dig Dis Sci 2005;50:626-9. (Pubitemid 40558451)
11. Moshkowitz M, Konikoff FM, Peled Y, et al. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995;36:845-7.
12. Moffat AC, Jackson JV, Moss MS, et al. Clarke's isolation and identification of drugs in pharmaceuticals, body fluids, and post-mortem material. London (United Kingdom): Pharmaceutical Press; 1986. p. 361-2.
13. Songü r Y, Senol A, Balkarli A, et al. Triple or quadruple tetracyclinebased therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009;338:50-3.
14. Caselli M, Pazzi P, LaCorte R, et al. Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 1989;44:101-4. (Pubitemid 20019286)
15. Wang WH, Hu FL, Wong BC, et al. Inhibitory effects of aspirin and indometacin on the growth of Helicobacter pylori in vitro. Chin J Dig Dis 2002;3:172-7. (Pubitemid 36267209)
16. Price CT, Lee IR, Gustafson JE. The effects of salicylate on bacteria. Int J Biochem Cell Biol 2000;32:1029-45.
17. Sjostrom JE, Kuhler T, Larsson H. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 1997;41:1797-801. (Pubitemid 27339890)
18. Helena C, Per-Anders M. Antimicrobial activities of non-antibiotic drugs. J Antimicrob Chemother 1993;32:355-65.
19. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002;359:14-22. (Pubitemid 34119190)
20. Zapata-Colindres JC, Zepeda-Gómez S, Montaño-Loza A, et al. The association of Helicobacter pylori infection and nonsteroidal antiinflammatory drugs in peptic ulcer disease. Can J Gastroenterol 2006; 20:277-80.
21. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25. (Pubitemid 29297615)
22. Hudson N, Balsitis M, Filipowicz F, et al. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748-51. (Pubitemid 23185097)
23. Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006:CD003840.